Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$67.55
+0.9%
$62.48
$42.52
$68.64
$136.70B0.238.73 million shs7.82 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$361.78
+0.9%
$330.63
$253.95
$385.22
$39.38B0.51403,850 shs295,201 shs
Pfizer Inc. stock logo
PFE
Pfizer
$29.02
+1.7%
$25.79
$23.58
$29.09
$162.73B0.3437.37 million shs39.25 million shs
Sanofi stock logo
SNY
Sanofi
$44.47
+0.2%
$43.84
$40.89
$52.68
$107.57B0.352.42 million shs2.17 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+1.25%-0.19%+3.22%+19.11%+42.58%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
+0.87%-3.73%+15.30%+29.24%+8.96%
Pfizer Inc. stock logo
PFE
Pfizer
+1.58%+2.44%+15.86%+12.93%+16.39%
Sanofi stock logo
SNY
Sanofi
+0.23%-2.09%+3.54%+0.20%-10.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$67.55
+0.9%
$62.48
$42.52
$68.64
$136.70B0.238.73 million shs7.82 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$361.78
+0.9%
$330.63
$253.95
$385.22
$39.38B0.51403,850 shs295,201 shs
Pfizer Inc. stock logo
PFE
Pfizer
$29.02
+1.7%
$25.79
$23.58
$29.09
$162.73B0.3437.37 million shs39.25 million shs
Sanofi stock logo
SNY
Sanofi
$44.47
+0.2%
$43.84
$40.89
$52.68
$107.57B0.352.42 million shs2.17 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+1.25%-0.19%+3.22%+19.11%+42.58%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
+0.87%-3.73%+15.30%+29.24%+8.96%
Pfizer Inc. stock logo
PFE
Pfizer
+1.58%+2.44%+15.86%+12.93%+16.39%
Sanofi stock logo
SNY
Sanofi
+0.23%-2.09%+3.54%+0.20%-10.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.56
Moderate Buy$66.06-2.22% Downside
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
3.00
Buy$402.1411.16% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.28-2.56% Downside
Sanofi stock logo
SNY
Sanofi
2.40
Hold$49.5011.31% Upside

Current Analyst Ratings Breakdown

Latest ONC, PFE, BMY, and SNY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/31/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
8/18/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
UpgradeHold (C+)Buy (B-)
8/17/2026
Pfizer Inc. stock logo
PFE
Pfizer
DowngradeHold (C)Hold (C-)
8/10/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Reiterated RatingOutperform$370.00
8/7/2026
Pfizer Inc. stock logo
PFE
Pfizer
Lower Price TargetBuy$35.00 ➝ $31.00
8/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
UpgradeHoldStrong-Buy
8/6/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Reiterated RatingOverweight
8/6/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Reiterated RatingOutperform
8/6/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOverweight$403.00 ➝ $407.00
8/6/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetBuy$424.00 ➝ $454.00
8/6/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Lower Price TargetOutperform$451.00 ➝ $450.00
(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$49.19B2.81$8.21 per share8.23$10.93 per share6.18
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$5.34B7.43$3.94 per share91.76$47.13 per share7.68
Pfizer Inc. stock logo
PFE
Pfizer
$63.70B2.60$4.47 per share6.49$15.00 per share1.93
Sanofi stock logo
SNY
Sanofi
$49.35B2.18$7.08 per share6.28$33.36 per share1.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$4.5414.8810.490.3218.87%66.90%14.74%10/29/2026 (Estimated)
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$286.93M$5.6863.6926.54N/A10.70%14.23%7.82%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7638.199.871.926.80%19.63%8.46%11/3/2026 (Estimated)
Sanofi stock logo
SNY
Sanofi
$8.84B$1.9123.288.501.368.66%14.19%7.95%10/23/2026 (Estimated)

Latest ONC, PFE, BMY, and SNY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$1.40$2.05+$0.65$2.05$1.66 billion$1.71 billion
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
7/30/2026Q2 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.60$2.04+$0.44$1.62$11.74 billion$12.97 billion
7/30/2026Q2 2026
Sanofi stock logo
SNY
Sanofi
N/A$2.41N/A$0.17N/A$13.36 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.523.73%+1.61%55.51%17 Years
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.725.93%-13.20%226.32%16 Years
Sanofi stock logo
SNY
Sanofi
$1.763.96%+6.46%92.15%N/A

Latest ONC, PFE, BMY, and SNY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.01%7/24/20267/24/20269/1/2026
6/17/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.634.34%7/2/20267/2/20268/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
1.89
1.53
1.38
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.17
3.40
3.06
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96
Sanofi stock logo
SNY
Sanofi
0.21
0.99
0.64

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Sanofi stock logo
SNY
Sanofi
14.03%

Insider Ownership

CompanyInsider Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.05%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6.19%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Sanofi stock logo
SNY
Sanofi
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
12,000109.79 million102.99 millionN/A
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Sanofi stock logo
SNY
Sanofi
74,8462.42 billion2.40 billionOptionable

Recent News About These Companies

Sanofi (NASDAQ:SNY) Receives Average Recommendation of "Hold" from Brokerages
Sanofi (NASDAQ:SNY) Upgraded at Wall Street Zen
Sanofi (NASDAQ:SNY) Cut to "Hold" at Wall Street Zen
Sanofi 2026 Q2 - Results - Earnings Call Presentation
Sanofi Says EU Expands MenQuadfi Approval

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$67.55 +0.63 (+0.95%)
Closing price 09/2/2026 03:59 PM Eastern
Extended Trading
$67.73 +0.18 (+0.26%)
As of 08:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$361.78 +3.13 (+0.87%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$361.70 -0.08 (-0.02%)
As of 08:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Pfizer stock logo

Pfizer NYSE:PFE

$29.02 +0.47 (+1.65%)
Closing price 09/2/2026 03:59 PM Eastern
Extended Trading
$28.96 -0.06 (-0.21%)
As of 08:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sanofi stock logo

Sanofi NASDAQ:SNY

$44.47 +0.10 (+0.23%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$44.96 +0.49 (+1.10%)
As of 08:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.